Early versus Late Use of Vedolizumab in Ulcerative Colitis

Early versus Late Use of Vedolizumab in Ulcerative Colitis

We explored the potential for differential efficacy of vedolizumab between "early" and "late" ulcerative colitis (UC) with evaluation of clinical, endoscopic, and histological endpoints.This was a multicentre, multinational open-label study in patients with moderately-to-severely...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Vermeire Séverine
Hanzel Jurij
Löwenberg Mark
Ferrante Marc
Bossuyt Peter
Hoentjen Frank
Franchimont Denis
Palatka Károly
Peeters Harald
Mookhoek Aart
Hertogh Gert de
Molnár Tamás
Moerkercke Wouter van
Lobatón Triana
Clasquin Esmé
et al
Dokumentumtípus: Cikk
Megjelent: 2024
Sorozat:JOURNAL OF CROHNS & COLITIS 18 No. 4
Tárgyszavak:
Gasztroenterológia és hepatológia
doi:10.1093/ecco-jcc/jjad179

mtmt:34316209
Online Access:http://publicatio.bibl.u-szeged.hu/29497
Leíró adatok
Tartalmi kivonat:We explored the potential for differential efficacy of vedolizumab between "early" and "late" ulcerative colitis (UC) with evaluation of clinical, endoscopic, and histological endpoints.This was a multicentre, multinational open-label study in patients with moderately-to-severely active UC, defining "early" UC by a disease duration <4 years and bio-naïve and "late" UC by a disease duration >4 years and additional exposure to tumour necrosis factor antagonists. Patients received standard treatment with intravenous vedolizumab for 52 weeks (300 mg weeks 0-2-6, every 8 weeks thereafter without escalation). The primary endpoint was corticosteroid-free clinical remission with endoscopic improvement (total Mayo score ≤2 with no subscore >1) at both week 26 and 52.A total of 121 patients were included: in the "early" group 25/59 (42.4%) achieved the primary endpoint versus 19/62 (30.6%) in the "late" group (P = 0.18). There were no significant differences between the two groups in endoscopic improvement (week 26: "early" 32/59 [54.2%] vs. "late" 29/62 [46.8%]; P = 0.412; week 52: 27/59 [45.8%] vs. 25/62 [40.3%]; P = 0.546) or histological remission (Robarts Histopathology Index <3 without neutrophils in the epithelium and lamina propria) (week 26: 24/59 [40.7%] vs. 21/62 [33.9%]; P = 0.439; week 52: 22/59 [37.3%] vs. 22/62 [35.5%]; P = 0.837).No significant differences in clinical, endoscopic, and histological outcomes were observed between "early" and "late" disease.
Terjedelem/Fizikai jellemzők:540-547
ISSN:1873-9946

Hasonló tételek